The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study
Abstract Background Real‐world application of osimertinib with antiangiogenic agents in non‐small cell lung cancer (NSCLC) is common, but the efficacy data are rarely reported. Methods To obtain an objective efficacy report of different real‐world treatment models of osimertinib and antiangiogenic a...
Main Authors: | Yu Feng, Liling Huang, Haohua Zhu, Le Tang, Xingsheng Hu, Yuankai Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-09-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.14603 |
Similar Items
-
Pyrotinib plus antiangiogenic agents for HER2‐altered advanced non‐small cell lung cancer: A retrospective real‐world study
by: Yaning Yang, et al.
Published: (2023-11-01) -
Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance
by: Mingzhao Wang, et al.
Published: (2023-04-01) -
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
by: Lan-Lan Pang, et al.
Published: (2023-01-01) -
Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study
by: Ke Ma, et al.
Published: (2023-05-01) -
An epidermal growth factor receptor-mutated lung adenocarcinoma patient with brain lesions resisted to osimertinib monotherapy but achieved more than 4 years of survival in osimertinib plus bevacizumab metronomic treatment
by: Jie Liu, et al.
Published: (2024-01-01)